to differ materially from those indicated or implied by such forward-looking statements, including without limitation the risk that the occurrence of any event, change or other circumstance that could give rise to delaying or not completing the intended distribution of Distribution Shares, including the risk that a distribution of the Distribution Shares may not be completed in a timely manner or at all, including that a governmental entity may prohibit, delay or refuse to grant approval for such distributi ...

Core Viewpoint - Verdera Energy Corp. and POCML 7 Inc. have announced the filing of their Filing Statement related to their proposed Qualifying Transaction, which was previously disclosed in November 2025 [1] Group 1 - The Filing Statement was dated February 13, 2026, and is available under POCML7's profile on SEDAR+ [1] - Investors are encouraged to review the Filing Statement for comprehensive details regarding the Transaction [1]

Core Viewpoint - Verdera Energy Corp. and POCML 7 Inc. have successfully closed their offering of subscription receipts, raising a total of $20 million [1] Group 1 - The offering was conducted for aggregate gross proceeds of $20 million [1] - Verdera has reserved the ticker symbol "V" on the TSX Venture Exchange [1] - Trading on the TSX-V is expected to commence on or about February 24, 2026 [1]

Core Insights - Thiogenesis Therapeutics, Corp. announced interim data from its Phase 2 clinical study of TTI-0102 for MELAS at Mitocon 2026, highlighting its potential in treating rare mitochondrial diseases [1][2]. Study Highlights - The Phase 2 (EU) study was a randomized, single-blind, placebo-controlled trial involving nine patients with genetically confirmed MELAS, demonstrating the importance of weight-based dosing for optimal exposure and tolerability [3]. - Fixed dosing led to gastrointestinal adverse events in lower-weight patients, while weight-adjusted dosing mitigated these effects, supporting its use in future trials [6]. Clinical and Pharmacological Findings - Statistically significant improvement in fatigue was observed, with TTI-0102-treated patients showing a mean reduction of up to 10% in the Modified Fatigue Impact Scale (MFIS) score compared to placebo (p < 0.001) [7]. - Weight-based dosing at approximately 60 ± 5 mg/kg achieved sustained 24-hour cysteamine exposure, with lower peak concentrations compared to fixed dosing and approved formulations [6][7]. - Increased plasma pyruvate without lactate elevation suggests enhanced glycolytic flux, indicating improved mitochondrial energy handling [7]. Future Implications - The findings provide a biological rationale for the observed clinical improvement in fatigue and inform the design of upcoming studies, including a Phase 2a study in Leigh syndrome spectrum [8]. - The MFIS is a validated measure for assessing fatigue in mitochondrial disorders, relevant for evaluating therapeutic benefits [9]. Company Overview - Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company focused on developing thiol-based prodrugs for rare pediatric diseases, with TTI-0102 as its lead candidate [14].

Core Viewpoint - Verdera Energy Corp. and POCML 7 Inc. are progressing with a proposed transaction that will qualify as a Qualifying Transaction under TSX Venture Exchange policies, involving a subscription receipt offering to raise $20 million [1][2]. Offering Details - The offering will consist of 20,000,000 Subscription Receipts priced at $1.00 each, with an option for agents to purchase an additional 15% for up to $3 million [2]. - Upon meeting escrow release conditions, each Subscription Receipt will convert into one common share of Verdera [3]. - Agents will receive a 5% commission on gross proceeds and broker warrants equivalent to 4% of the total Subscription Receipts sold [4]. Escrow and Conditions - At closing, gross proceeds will be placed in escrow, with conditions for release including the completion of the proposed transaction [5]. - If conditions are not met within 90 days, funds will be returned to Subscription Receipt holders [5]. - Completion of the proposed transaction is subject to TSXV acceptance and other conditions [8][11]. Use of Proceeds - The net proceeds from the offering will be allocated for exploration and advancement of the Crownpoint and Hosta Butte Project, including drilling, community relations, and general corporate purposes [6]. Company Overview - Verdera Energy Corp. focuses on developing uranium assets in New Mexico, which is the 7th largest uranium-producing district globally, with significant mineral rights in the Grants Uranium District [14]. - The company aims to meet the growing demand for clean domestic uranium through environmentally sound extraction technology [15].

Core Insights - enCore Energy Corp. has appointed Mr. Wayne Heili to its Board of Directors, effective immediately, while Dr. Dennis Stover will retire from the Board on December 31, 2025, but will continue to support the company as Chair of the Technical Advisory Committee [1][2] Company Leadership Changes - Mr. Wayne Heili brings over 35 years of experience in uranium recovery, having held various technical and executive roles in the uranium industry, including CEO positions at Ur-Energy Inc. and Peninsula Energy Limited [3][4] - Dr. Dennis Stover has had a significant impact on the uranium industry over his five-decade career, contributing to safe and sustainable fuel solutions [2] Compensation and Incentives - Upon his appointment, Mr. Heili received an equity award consisting of 25,000 restricted stock units vesting over two years and 100,000 stock options with an exercise price of US$2.73, also vesting over a 24-month period [5] Company Overview - enCore Energy Corp. is focused on providing clean, reliable, and affordable nuclear fuel, being the only U.S. uranium company with multiple Central Processing Plants in operation [6] - The company utilizes In-Situ Recovery (ISR) technology for uranium extraction, which is recognized as a proven method in the industry [6] Future Projects - enCore has plans for future projects, including the Dewey Burdock Project in South Dakota and the Gas Hills Project in Wyoming, building on its success in South Texas [7]

Core Insights - The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older who do not respond adequately to standard antihistamine treatment [1][4][11] - Dupixent is the first innovative treatment for CSU in over a decade, targeting IL-4 and IL-13, which are key drivers of type 2 inflammation [2][4] - The approval is based on data from two Phase 3 clinical trials showing significant reductions in itch and hives compared to placebo at 24 weeks [1][2][7] Group 1: Approval and Indications - Dupixent is now approved for use in patients with CSU who are naïve to anti-immunoglobulin E (IgE) therapy and have inadequate responses to histamine-1 antihistamines [1][4] - Approximately 270,000 adults and adolescents in the EU suffer from CSU that remains symptomatic despite standard treatment [1][6] Group 2: Clinical Trials and Efficacy - The LIBERTY-CUPID Phase 3 program included three studies assessing Dupixent as an add-on therapy to antihistamines, demonstrating significant efficacy in reducing urticaria activity and improving patient outcomes [2][7][8] - Study A and Study C involved 284 patients aged 12 years and older, while Study B included 108 patients, providing additional safety data [2][7] Group 3: Safety Profile - Safety results from the trials were consistent with Dupixent's known safety profile, with common adverse reactions including injection site reactions, conjunctivitis, and arthralgia [3][4] - Adverse events observed more frequently with Dupixent compared to placebo included injection site reactions, COVID-19, and hypertension [3][4] Group 4: Broader Context and Future Potential - Beyond the EU, Dupixent is also approved for CSU in the United States and Japan, indicating a growing acceptance of the treatment in various markets [4][11] - The Dupixent development program has been extensive, with over 60 clinical trials involving more than 10,000 patients across various chronic diseases driven by type 2 inflammation [15][16]

Core Insights - Grabar Law Office is investigating claims on behalf of shareholders of enCore Energy Corp. regarding potential breaches of fiduciary duties by certain officers and directors [1] - Shareholders who purchased enCore Energy Corp. shares prior to March 28, 2024, and still hold them can seek corporate reforms and the return of funds at no cost [2] - A securities fraud class action complaint alleges that enCore Energy Corp. made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3] Company Details - The investigation focuses on whether enCore Energy Corp.'s officers failed to disclose that the company lacked effective internal controls over financial reporting [3] - The complaint also states that enCore could not capitalize certain exploratory and development costs under GAAP, leading to increased net losses [3] - As a result of these issues, the positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading [3]

Company Overview - enCore Energy is positioned as the largest ISR uranium extractor in the United States, with operations underway at two plants[14] - The company has significant S-K 1300 resources, including 30.94 million pounds in the Measured and Indicated (M&I) category and 20.54 million pounds in the Inferred category[19] - enCore Energy's market capitalization was approximately $598.85 million as of October 31, 2025, with 187,139,534 shares issued and outstanding[52] Uranium Market and Strategy - The United States faces a growing demand for uranium, with demand increasing by +48 million pounds per year, while domestic supply is declining by -200,000 pounds per year[45] - The company employs a uranium sales strategy supported by sales agreements while preserving exposure to the market[22] - Current contracts represent less than 38% of planned extraction through 2033, allowing for significant upside exposure to spot market pricing[184] Project Pipeline and Production - Alta Mesa CPP commenced operations in Q2 2024 and is configured to operate at 1 million lbs per year, currently running at 60% of that capacity[131] - Daily production at Alta Mesa averaged 2,678 pounds per day in June 2025[136] - The Dewey Burdock ISR Uranium Project has measured resources of 14,285,988 lbs and indicated resources of 2,836,159 lbs of U₂O₃[166]

Financial Performance - Net loss per share improved to $(0.03) from $(0.09) in the same period of 2024[5] - Closing cash and equivalent balance reached $100.3 million with working capital of $119.7 million[5] Uranium Production and Sales - Delivered 130,000 pounds of uranium at a price of $68.28 with a weighted average cost of $38.35[5] - U3O8 extraction increased by 11.4% to 227,070 pounds from the second quarter of 2025[5] - Weighted average cost of U3O8 sold decreased to $53.71 per pound from $97.91 per pound in the same period of 2024[5] - Total cost of U3O8 sold for nine months was $25.781 million for 480,000 pounds, averaging $53.71 per pound[6] - Cash costs for extracted pounds were $6,680,000, averaging $26.20 per pound[6] Project Development - Dewey-Burdock Project included in the federal FAST-41 program for expedited permitting review[7] - Future projects include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming[13] - No U3O8 is forecasted to be purchased in 2025[5]